Research Projects Page

Since our inception as an outcome committee in 2015, we have consistently and considerably expanded our ability to produce rigorous outcomes research. In 2018, we established a more formal program and leadership, including full time outcomes research staff. The result of these allocated resources has been a productive output across multiple specialty disease states. Below are highlighted outcomes from studies completed in recent years. 

To see our full bibliography, Click Here

Research Project List

Filter
Research categories (field_research_categories)
Research categories (field_research_categories)
112 Results

Assessing Patient-Reported Outcomes and Pharmacist Interventions in Rheumatology Specialty Disease States within an Integrated Care CenterSpecialty pharmacist integrated into rheumatology clinics perform target interventions to ensure safe and effective medication use.

Published November 17, 2022
Patient reported outcomes (PROs) are used to assess response to medication and the need for therapeutic adjustments in patients with rheumatologic disease states. Vanderbilt Specialty Pharmacy, an integrated health-system specialty pharmacy, assesses PROs through monthly refill questionnaires to guide specialty pharmacist interventions and improve patient care.
View Poster. November 2022

Hepatitis C Cascade of Care in a Multidisciplinary Substance Use Bridge Clinic Model

Published November 14, 2022
The objective of this study was to characterize the HCV cascade of care in a bridge clinic setting and identify barriers to HCV treatment in this population. This study demonstrated that several challenges and barriers exist to engage patients in HCV care in a bridge clinic model, and more strategies should be identified to engage patients and link them to care.
View Poster. November 2022

Health System Specialty Pharmacies Ensure Patients Initiate New Oncology Treatments

Published November 11, 2022
Evaluated the rate and reasons for Primary Medication Nonadherence (PMN) to specialty oral oncology medications in Health System Specialty Pharmacies (HSSP). Multisite retrospective cohort study across 7 HSSP sites. Most patients (89%) prescribed oral oncology treatment at HSSP initiated therapy. Primary medication nonadherence was mostly due to patient decision.
View Poster. November 2022

Management of Patients with Multiple Sclerosis within Health-System Specialty Pharmacies: Pharmacist Actions

Published October 17, 2022
This multisite, prospective, cohort study of patients with MS evaluates the frequency and type of pharmacists' actions for patients on DMTs for MS across four HSSP sites. This study demonstrates that pharmacists commonly perform actions related to providing medication education and ensuring DMT safety and adherence.
View Poster. October 2022

Patient-centered monitoring for encorafenib and binimetinib: Tailoring patient education, monitoring, and outreach to improve health outcomes

Published June 23, 2022
The purpose of this project was to assess the type and frequency of AEs and AE-associated medical actions (i.e., treatment holds, dose reduction and treatment discontinuation due to AEs) in patients initiating encorafenib and binimetinib combination therapy.
View Poster. June 2022

Evaluating and Improving Poly (ADP-ribose) polymerase inhibitor (PARPi) therapy Persistence

Published June 23, 2022
The objectives of this study were to identify the type and frequency of adverse events (AEs) and the corresponding rate of treatment modifications (holds, dose redutions, discontinuations) related to adverse events in patients initiating PARPI therapy as well as to measure adherence to PARPI therapy. hough modifications were common, patients achieved high medication adherence rates (≥97%).
View Poster. June 2022

Assessing Patient-reported Outcomes and Pharmacist Interventions in Neurology Specialty Disease States within an Integrated Care Center

Published May 25, 2022
View Poster. May 2022

Assessing the Impact of Limited Distribution Drug Networks Based on Time to Accessing Oral Oncolytic Agents at an Integrated Specialty Pharmacy

Published May 23, 2022
Download Publication
Research Bibliography